Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Impinj Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $225 (market cap $29.97B), while Impinj Inc trades at $180 (market cap $5.49B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 5.5× Impinj Inc's market cap, and Impinj Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | PI | |
|---|---|---|
Market Cap | $29.97B | $5.49B |
Sector | Health | Technology |
52-Week High | $491.22 | $241.91 |
52-Week Low | $205.48 | $91.34 |
Enterprise Value | $27.93B | $5.62B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Impinj (PI) trades at $179.58, up 1.89% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $186. The stock shows strong revenue growth and recent earnings beats, but faces profitability challenges with negative net income margins. Recent news highlights institutional buying and record Q2 2026 results, driving positive sentiment.
Outlook: Upside potential exists from analyst targets and RFID market growth, but risks include persistent losses and high valuation multiples. Investment appeal hinges on margin improvement and execution against guidance, with current levels near resistance requiring careful entry timing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
